Last reviewed · How we verify

NCT06550232

IV PAPAVERINE Prior to Propess for Labor Induction

Completed Phase 4 Last updated 26 June 2025
What this trial tests

Phase 4 trial testing Papaverine in Induced Vaginal Delivery in 110 participants. Completed in 23 March 2025.

Timeline
12 August 2024
Primary endpoint
23 March 2025
23 March 2025

Quick facts

Lead sponsorWestern Galilee Hospital-Nahariya
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment110
Start date12 August 2024
Primary completion23 March 2025
Estimated completion23 March 2025
Sites1 location across Israel

Drugs / interventions tested

Conditions studied

Sponsor

Western Galilee Hospital-Nahariya

Who can join

Adults 18 to 45, female only, with Induced Vaginal Delivery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aim to evaluate the effect of administering papaverine prior to PGE2 insertion on changes in Bishop-scores and on the induction-to-delivery interval. Researchers will compare drug papaverine to a placebo

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Papaverine

Trials testing the same drug.

Other Western Galilee Hospital-Nahariya trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06550232.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing